- Home
- MNMD vs CRTO Comparison
MNMD vs CRTO Comparison
Compare MNMD & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- CRTO
- Stock Information
- Founded
- MNMD 2019
- CRTO 2005
- Country
- MNMD United States
- CRTO France
- Employees
- MNMD N/A
- CRTO N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- CRTO Advertising
- Sector
- MNMD Health Care
- CRTO Consumer Discretionary
- Exchange
- MNMD Nasdaq
- CRTO Nasdaq
- Market Cap
- MNMD 960.2M
- CRTO 1.1B
- IPO Year
- MNMD N/A
- CRTO 2013
- Fundamental
- Price
- MNMD $11.01
- CRTO $22.01
- Analyst Decision
- MNMD Strong Buy
- CRTO Buy
- Analyst Count
- MNMD 7
- CRTO 9
- Target Price
- MNMD $26.71
- CRTO $38.67
- AVG Volume (30 Days)
- MNMD 2.3M
- CRTO 473.3K
- Earning Date
- MNMD 11-06-2025
- CRTO 10-29-2025
- Dividend Yield
- MNMD N/A
- CRTO N/A
- EPS Growth
- MNMD N/A
- CRTO 83.79
- EPS
- MNMD N/A
- CRTO 3.00
- Revenue
- MNMD N/A
- CRTO $1,956,800,000.00
- Revenue This Year
- MNMD N/A
- CRTO N/A
- Revenue Next Year
- MNMD N/A
- CRTO $1.84
- P/E Ratio
- MNMD N/A
- CRTO $7.44
- Revenue Growth
- MNMD N/A
- CRTO 0.53
- 52 Week Low
- MNMD $4.70
- CRTO $19.50
- 52 Week High
- MNMD $14.43
- CRTO $47.27
- Technical
- Relative Strength Index (RSI)
- MNMD 41.39
- CRTO 51.20
- Support Level
- MNMD $12.60
- CRTO $21.94
- Resistance Level
- MNMD $14.43
- CRTO $23.36
- Average True Range (ATR)
- MNMD 0.84
- CRTO 0.84
- MACD
- MNMD -0.30
- CRTO 0.19
- Stochastic Oscillator
- MNMD 11.52
- CRTO 47.74
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.